Exenatide Insurance Coverage
Exenatide insurance coverage for diabetes. Generally covered but declining in formulary preference. When exenatide might be your best covered option.
Commercial coverage
Generally covered
Medicare Part D
Covered for diabetes
Formulary trend
Declining preference
Typical copay
$25-100/mo
Step therapy use
Sometimes required
Coverage Status
Exenatide (Byetta and Bydureon) remains covered by most commercial insurance plans and Medicare Part D for type 2 diabetes. However, its formulary position has declined as newer GLP-1 medications have gained preferred status. Some plans have moved exenatide to higher tiers or non-preferred status.
Copays with insurance typically range from $25-$100/month. The AstraZeneca savings program may provide additional reductions for commercially insured patients.
Step Therapy Considerations
In some cases, exenatide's formulary position works in patients' favor: some plans require trying exenatide before approving more expensive GLP-1 medications. If your plan requires this step therapy, a documented trial of exenatide (with documented inadequate response) can facilitate approval for semaglutide or tirzepatide.
Conversely, some plans have eliminated exenatide from their formularies entirely, directing patients to newer options from the start.
Frequently Asked Questions
Is exenatide still covered by insurance?
Yes, most plans cover exenatide for type 2 diabetes, though formulary preference is declining. Coverage may be at higher tier copays compared to preferred alternatives.
Does Medicare cover Bydureon?
Yes, Medicare Part D covers Bydureon for type 2 diabetes with prior authorization. Check your specific plan's formulary for tier placement and copay amounts.
Find the best-covered GLP-1 medication for your plan
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.
Search Providers →Explore all Exenatide topics
Cost guides, side effect management, dosing information, insurance coverage, and more — all backed by clinical data.